ClinicalTrials.gg
CompletedNCT00961441Updated Aug 6, 2015Results posted

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

A Phase 2 interventional study of Keppra XR in Epilepsy, sponsored by UCB BIOSCIENCES, Inc.. Completed at 6 sites in United States. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-08-06.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
45th of 60
25 · median 94
Started
2009
the only one that year
Phase 2
11 of 60
none open now
Registered
34th of 60
by date

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 45th largest by enrollment, is the only one that started in 2009, is one of 11 in phase 2, and was the 34th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Levetiracetam
  • Epilepsy
  • Children
  • Adults
04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of epilepsy on up to three concomitant anti-epileptic drugs
  • Subjects on levetiracetam immediate release (IR) can be enrolled if on a stable dose for 7 days

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of status epilepticus within 3 months of Visit 1
  • Subject has difficult venous accessibility
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Children 12-16 years old

    Drug: Keppra XR

  • Experimental
    Adults 18-55 years old

    Drug: Keppra XR

Interventions

  • Keppra XR 500 mg tablets and Keppra XR 750 mg tablets Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days

    Also known as: Levetiracetam XR

06

What researchers measure

Primary outcomes

  1. Maximum Concentration at Steady State (Cmax) of Keppra XR Normalized by Dose and by Body Weight and Dose During up to 7 Days of Administration

    The Cmax is the maximum plasma concentration normalized by dose and by body weight and dose. Cmax normalized by 1000 mg dose was calculated as: Cmax/(mg dose taken/ 1000 mg Keppra XR). Cmax normalized by body weight and dose (1 mg Keppra XR/kg) was calculated as: Cmax/(bodyweight (kg)/ mg dose Keppra XR taken). Pharmacokonetic (PK) samples were taken predose and 1h, 2.5h, 4h, 6h and 10h after study medication at day 4, 5, 6 or 7 of Keppra XR administration.

    Time frame: 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

  2. Area Under the Plasma Concentration Curve Over a Dosing Interval of 24 Hours (AUCtau) of Keppra XR Normalized by Dose, and by Body Weight and Dose During up to 7 Days of Administration

    AUCtau normalized by 1000 mg dose was calculated as: AUCtau/(mg dose taken/ 1000 mg Keppra XR). AUCtau normalized by body weight and dose (1 mg Keppra XR/kg) was calculated as: AUCtau/(bodyweight (kg)/ mg dose Keppra XR taken). 6 PK samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration. At steady state, reached after 2 days of administration of Keppra XR, the concentrations at 24h postdose is equal to the predose concentration. The predose concentration was used as the 24h concentration to calculate AUCτau.

    Time frame: 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

  3. Time of Maximum Plasma Concentration (Tmax) of Keppra XR During up to 7 Days of Administration

    The Tmax is the time corresponding to the maximum plasma concentration of Keppra XR. It was directly obtained from the observed concentration versus time curve. 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

    Time frame: 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

  4. Apparent Total Body Clearance (CL/F) of Keppra XR During up to 7 Days of Administration

    The Apparent Total Body Clearance (CL/F) was calculated as Dose/ AUCtau. 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

    Time frame: 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

Secondary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events From Starting Study Drug Treatment (Day 1) to up to 14 Days

    An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. Treatment emergent means that an AE has begun or got worse after start of Keppra XR administration.

    Time frame: From Starting Study Drug Treatment (Day 1) to up to 14 days

07

Results

Posted May 25, 2011

Participant flow

Intent-to-treat (ITT) population includes all enrolled patients who received at least one dose of study medication.Pharmacokinetic Per-Protocol (PK-PP) population is a subset of the ITT population, consisting of those patients who had no major protocol deviations affecting the pharmacokinetic parameters.

Participant flow — Overall Study
MilestoneKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Started1213
Pharmacokinetic (pk-pp) population1210
Completed1213
Not completed00

Outcome measures

PrimaryMaximum Concentration at Steady State (Cmax) of Keppra XR Normalized by Dose and by Body Weight and Dose During up to 7 Days of Administration

The Cmax is the maximum plasma concentration normalized by dose and by body weight and dose. Cmax normalized by 1000 mg dose was calculated as: Cmax/(mg dose taken/ 1000 mg Keppra XR). Cmax normalized by body weight and dose (1 mg Keppra XR/kg) was calculated as: Cmax/(bodyweight (kg)/ mg dose Keppra XR taken). Pharmacokonetic (PK) samples were taken predose and 1h, 2.5h, 4h, 6h and 10h after study medication at day 4, 5, 6 or 7 of Keppra XR administration.

Time frame:
6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.
Reported as:
Geometric mean · µg/mL
Maximum Concentration at Steady State (Cmax) of Keppra XR Normalized by Dose and by Body Weight and Dose During up to 7 Days of Administration
µg/mLKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Dose norm. ( Keppra XR 1000mg)17.3 (14.3 to 21.0)14.9 (12.1 to 18.5)
Dose and weight norm. ( Keppra XR 1 mg/kg)1.27 (1.12 to 1.44)1.24 (1.08 to 1.42)
Statistical analysis
  • Keppra XR in Children (12-16 Years Old) vs Keppra XR in Adults (18-55 Years Old) · ANOVA · Point estimate for ratio: 1.0271 · 90% CI 0.8817 to 1.1964Point estimates for the geometric means ratios children/adults for Cmax normalized by dose and body weight and 90% CIs have been calculated.
PrimaryArea Under the Plasma Concentration Curve Over a Dosing Interval of 24 Hours (AUCtau) of Keppra XR Normalized by Dose, and by Body Weight and Dose During up to 7 Days of Administration

AUCtau normalized by 1000 mg dose was calculated as: AUCtau/(mg dose taken/ 1000 mg Keppra XR). AUCtau normalized by body weight and dose (1 mg Keppra XR/kg) was calculated as: AUCtau/(bodyweight (kg)/ mg dose Keppra XR taken). 6 PK samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration. At steady state, reached after 2 days of administration of Keppra XR, the concentrations at 24h postdose is equal to the predose concentration. The predose concentration was used as the 24h concentration to calculate AUCτau.

Time frame:
6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.
Reported as:
Geometric mean · µg*h/mL
Area Under the Plasma Concentration Curve Over a Dosing Interval of 24 Hours (AUCtau) of Keppra XR Normalized by Dose, and by Body Weight and Dose During up to 7 Days of Administration
µg*h/mLKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Dose norm. (Keppra XR 1000mg)265 (214 to 327)236 (187 to 298)
Dose and weight norm. (Keppra XR 1 mg/kg)19.4 (16.5 to 22.9)19.6 (16.4 to 23.5)
Statistical analysis
  • Keppra XR in Children (12-16 Years Old) vs Keppra XR in Adults (18-55 Years Old) · ANOVA · Point estimate for ratio: 0.9914 · 90% CI 0.8110 to 1.2118Point estimates for the geometric means ratios children/adults for AUCtau normalized by dose and body weight and 90% CIs have been calculated.
PrimaryTime of Maximum Plasma Concentration (Tmax) of Keppra XR During up to 7 Days of Administration

The Tmax is the time corresponding to the maximum plasma concentration of Keppra XR. It was directly obtained from the observed concentration versus time curve. 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

Time frame:
6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.
Reported as:
Median · hours (h)
Time of Maximum Plasma Concentration (Tmax) of Keppra XR During up to 7 Days of Administration
hours (h)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Time of Maximum Plasma Concentration (Tmax) of Keppra XR During up to 7 Days of Administration5.90 (2.50 to 6.07)5.93 (2.45 to 6.05)
PrimaryApparent Total Body Clearance (CL/F) of Keppra XR During up to 7 Days of Administration

The Apparent Total Body Clearance (CL/F) was calculated as Dose/ AUCtau. 6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.

Time frame:
6 pharmacokinetic samples were taken pre-dose, 1, 2.5, 4, 6 and 10 hours after administration, at Day 4, 5, 6, or 7 of Keppra XR administration.
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance (CL/F) of Keppra XR During up to 7 Days of Administration
L/hKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Apparent Total Body Clearance (CL/F) of Keppra XR During up to 7 Days of Administration3.78 ± 31.44.23 ± 41.8
SecondaryOccurrence of Treatment-Emergent Adverse Events From Starting Study Drug Treatment (Day 1) to up to 14 Days

An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. Treatment emergent means that an AE has begun or got worse after start of Keppra XR administration.

Time frame:
From Starting Study Drug Treatment (Day 1) to up to 14 days
Reported as:
Number · Count
Occurrence of Treatment-Emergent Adverse Events From Starting Study Drug Treatment (Day 1) to up to 14 Days
CountKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
Total number of AEs711
Patients with at least 1 AE33
Patients with severe AEs01
Patients with serious AEs00

Adverse events

Collected over From Starting Study Drug Treatment (Day 1) to up to 14 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Keppra XR in Children (12-16 Years Old)—0/12 (0%)3/12 (25%)
Keppra XR in Adults (18-55 Years Old)—0/13 (0%)3/13 (23.1%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventKeppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)
SomnolenceNervous system disorders1/121/13
NauseaGastrointestinal disorders1/121/13
VomitingGastrointestinal disorders1/121/13
FatigueGeneral disorders1/120/13
LymphadenopathyBlood and lymphatic system disorders1/120/13
Pharyngitis streptococcalInfections and infestations1/120/13
Abnormal behaviourPsychiatric disorders1/120/13
ParaesthesiaNervous system disorders0/121/13
IrritabilityGeneral disorders0/121/13
ArthralgiaMusculoskeletal and connective tissue disorders0/121/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Mean14.88 ± 1.3741.78 ± 9.2128.87 ± 15.21
Sex: Female, Male
Sex: Female, Male(Participants)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Female6814
Male6511
Weight
Weight(kilogram (kg))Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Mean77.2 ± 24.182.5 ± 23.080.0 ± 23.2
Height
Height(centimeter (cm))Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Mean165.9 ± 8.8169.3 ± 10.3167.7 ± 9.6
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Mean27.62 ± 7.0128.63 ± 7.1428.14 ± 6.95
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Mean1.87 ± 0.341.95 ± 0.321.91 ± 0.32
Race
Race(Participants)Keppra XR in Children (12-16 Years Old)Keppra XR in Adults (18-55 Years Old)Total
Black437
Caucasian8917
Other / mixed011
08

Study locations

6 sites
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Fairfield, Connecticut, United States
  • Bethesda, Maryland, United States
  • Dallas, Texas, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2009
First posted
Aug 19, 2009
Start
Sep 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
May 25, 2011
Last update
Aug 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00961441
Responsible party
Sponsor
First posted
Aug 19, 2009
Start date
Sep 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
May 25, 2011
Last update
Aug 6, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion